Literature DB >> 1688630

Characterization of murine monoclonal antibodies to the tat protein from human immunodeficiency virus type 1.

D A Brake1, J Goudsmit, W J Krone, P Schammel, N Appleby, R H Meloen, C Debouck.   

Abstract

A panel of murine monoclonal antibodies (MAbs) to the human immunodeficiency virus type 1 trans-activator tat protein were characterized. The anti-tat MAbs were mapped to the different domains of the tat protein by Western blot (immunoblot) and Pepscan analyses. One-half of the MAbs tested mapped to the amino-terminal proline-rich region, and one-third of the MAbs tested mapped to the lysine-arginine-rich region of tat. The individual MAbs were tested for inhibition of tat-mediated trans activation, using a cell-based in vitro assay system. MAbs which mapped to the amino-terminal region of the tat protein demonstrated the highest degree of inhibition, whereas MAbs reactive to other portions of the molecule exhibited a less pronounced effect on tat function.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688630      PMCID: PMC249199     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  The acidic amino-terminal region of the HIV-1 Tat protein constitutes an essential activating domain.

Authors:  J Rappaport; S J Lee; K Khalili; F Wong-Staal
Journal:  New Biol       Date:  1989-10

3.  Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid.

Authors:  H M Geysen; R H Meloen; S J Barteling
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

4.  Introduction of macromolecules into cultured mammalian cells by osmotic lysis of pinocytic vesicles.

Authors:  C Y Okada; M Rechsteiner
Journal:  Cell       Date:  1982-05       Impact factor: 41.582

5.  Structural and functional characterization of human immunodeficiency virus tat protein.

Authors:  S Ruben; A Perkins; R Purcell; K Joung; R Sia; R Burghoff; W A Haseltine; C A Rosen
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

6.  Trans-activation of human immunodeficiency virus gene expression is mediated by nuclear events.

Authors:  J Hauber; A Perkins; E P Heimer; B R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

7.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

8.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

9.  Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat.

Authors:  J A Garcia; D Harrich; L Pearson; R Mitsuyasu; R B Gaynor
Journal:  EMBO J       Date:  1988-10       Impact factor: 11.598

10.  Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation.

Authors:  J A Garcia; D Harrich; E Soultanakis; F Wu; R Mitsuyasu; R B Gaynor
Journal:  EMBO J       Date:  1989-03       Impact factor: 11.598

View more
  12 in total

1.  Tat-neutralizing antibodies in vaccinated macaques.

Authors:  Ilia Tikhonov; Tracy J Ruckwardt; Glen S Hatfield; C David Pauza
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen.

Authors:  Emmanuel Moreau; Johan Hoebeke; Daniel Zagury; Sylviane Muller; Claude Desgranges
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

3.  Inhibition of human immunodeficiency virus type 1 and type 2 Tat function by transdominant Tat protein localized to both the nucleus and cytoplasm.

Authors:  M J Orsini; C M Debouck
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.

Authors:  Laurent Mascarell; Catherine Fayolle; Cécile Bauche; Daniel Ladant; Claude Leclerc
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity.

Authors:  W G Gutheil; M Subramanyam; G R Flentke; D G Sanford; E Munoz; B T Huber; W W Bachovchin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

6.  Identification of an Arg-Gly-Asp (RGD) cell adhesion site in human immunodeficiency virus type 1 transactivation protein, tat.

Authors:  D A Brake; C Debouck; G Biesecker
Journal:  J Cell Biol       Date:  1990-09       Impact factor: 10.539

7.  The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function.

Authors:  X Yang; C H Herrmann; A P Rice
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

8.  Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein.

Authors:  T C Rodman; S E To; H Hashish; K Manchester
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

9.  Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.

Authors:  Lakshmi Ramakrishna; Krishnamurthy Kumar Anand; Kumarasamypet M Mohankumar; Udaykumar Ranga
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein.

Authors:  Tracy J Ruckwardt; Ilia Tikhonov; Shannon Berg; Glen S Hatfield; Angelika Chandra; Prakash Chandra; Bruce Gilliam; Robert R Redfield; Robert C Gallo; C David Pauza
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.